Voydeya as add-on treatment is safe, effective in PNH
Voydeya (danicopan) effectively and safely treated paroxysmal nocturnal hemoglobinuria (PNH) in people with significant extravascular hemolysis, when used as an add-on therapy to Ultomiris (ravulizumab) or Soliris (eculizumab). That’s according to long-term data from the Phase 3 ALPHA trial (NCT04469465), which found that dual treatment with…